Why Little Green Pharma’s Acquisition of Cannatrek Just Got More Complex
Little Green Pharma has issued a supplementary scheme booklet updating Cannatrek shareholders on the acquisition progress, including a revised timetable and the termination of a planned sale and leaseback of its WA production facility. Both companies’ boards continue to recommend the scheme, supported by an independent expert’s positive assessment.
- Supplementary scheme booklet issued with updated timetable
- Termination of proposed sale and leaseback of WA production facility
- Independent Expert confirms scheme remains fair and reasonable
- Unanimous board recommendations from both Little Green Pharma and Cannatrek
- Key shareholder meetings and court approval dates set for April 2026
Context of the Acquisition
Little Green Pharma Ltd (ASX:LGP), a leading player in the global medicinal cannabis sector, has provided an important update to shareholders of Cannatrek Ltd regarding their proposed acquisition via a scheme of arrangement. This supplementary scheme booklet, approved by the Federal Court of Australia, offers fresh details on the timetable and operational changes since the initial scheme booklet was released in early March 2026.
Revised Timetable and Next Steps
The updated timetable outlines key dates for shareholder meetings and court approvals, with the Cannatrek Scheme Meeting scheduled for 10 April 2026 and the subsequent court hearing for scheme approval set for 24 April 2026. If approved, the scheme’s effective date and implementation will follow swiftly, with consideration securities to be issued by 1 May 2026. These dates remain indicative and subject to regulatory and court approvals, but they provide a clear roadmap for the acquisition’s final stages.
Termination of WA Facility Sale and Leaseback
One notable update is the termination of a previously announced sale and leaseback transaction involving Little Green Pharma’s South-West Western Australia production facility. The parties were unable to reach a commercial agreement on certain conditions, leading to the contract’s termination. Importantly, this development has not altered the Independent Expert’s opinion on the scheme’s fairness or the unanimous recommendation from both Cannatrek and Little Green Pharma boards to proceed with the acquisition.
Independent Expert and Board Endorsements
The independent expert report by RSM Corporate Australia Pty Ltd continues to conclude that the scheme is fair and reasonable and in the best interests of Cannatrek shareholders, assuming no superior proposal emerges. Both boards have reaffirmed their unanimous support for the scheme, with Cannatrek directors collectively holding approximately 22.35% of shares and intending to vote in favour. This strong endorsement signals confidence in the strategic rationale and expected benefits of the acquisition.
Strategic Implications for Little Green Pharma
Little Green Pharma’s acquisition of Cannatrek is a significant move to consolidate its position in the medicinal cannabis market, expanding its footprint across Australia and Europe. The company operates multiple production facilities, including the largest in Europe, and distributes products in over a dozen export markets. The acquisition is expected to enhance LGP’s product portfolio and distribution capabilities, positioning it well for scalable growth amid rising global demand for medicinal cannabis.
Shareholder Engagement and Voting
Cannatrek shareholders are urged to carefully review both the original and supplementary scheme booklets before voting. The supplementary booklet is being dispatched electronically or by post depending on shareholder preferences. Voting deadlines and eligibility dates are clearly set, with proxy forms due ahead of the meetings. Shareholders are encouraged to seek independent advice if uncertain about the scheme’s implications.
Bottom Line?
As the acquisition edges closer to completion, all eyes will be on shareholder votes and court approval, with the terminated WA facility deal adding a layer of complexity to watch.
Questions in the middle?
- How will the termination of the WA facility sale and leaseback impact Little Green Pharma’s financial position?
- Could a superior proposal emerge before the scheme meeting, potentially altering the acquisition outcome?
- What operational synergies and integration challenges might arise post-acquisition?
